Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : KNS366
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Recipient : Kynos Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Dr. Falk Pharma Acquires Kynos, Adds Acute Pancreatitis Focus
Details : Through the acquisition, Dr. Falk Pharma will add KNS366 to its R&D pipeline and further explore its potential in upcoming clinical trials for the treatment of acute pancreatitis.
Brand Name : KNS366
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 29, 2024
Lead Product(s) : KNS366
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Recipient : Kynos Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Naronapride
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Recipient : Renexxion
Deal Size : Not Applicable
Deal Type : Not Applicable
Renexxion and Dr. Falk Expand Phase 2b Study of Naronapride in Gastroparesis
Details : ATI 7505 (naronapride) is a potential best-in-class oral, locally acting pan-GI prokinetic, that acts as 5-HT4R agonist and D2R antagonist. It is being evaluated for the treatment of Gastroparesis.
Brand Name : ATI 7505
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 13, 2024
Lead Product(s) : Naronapride
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Recipient : Renexxion
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
